Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Doggrell
Sheila A
SA
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D000077405:Irbesartan; D019808:Losartan / Q000627:therapeutic use*; D047495:PPAR gamma / Q000819:agonists*; D051381:Rats; D011924:Rats, Zucker; D000077333:Telmisartan; D013777:Tetrazoles / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D047495:PPAR gamma; D013777:Tetrazoles; D000077405:Irbesartan; D019808:Losartan; D000077333:Telmisartan